Perth, Australia. 4 February 2008: The Company (ASX: SBP) has...

Perth, Australia. 4 February 2008: The Company (ASX: SBP) has received
notification from the Sponsor of the Physician’s IND (Investigatory New Drug), Dr
Robert Nagourney of Rational Therapeutics, that due to the progression of the patient’s
disease, a decision has been made to discontinue the Coramsine® treatment.
On 16 October 2007 Solbec announced to the market that a Physician’s IND had been
opened with the United States Food and Drug Administration on the basis that this
specific patient’s tumour had shown ex-vivo sensitivity to Coramsine® where other
conventional chemotherapeutics had failed. The patient has advanced stage renal cell
carcinoma and unfortunately, despite several months of Coramsine® treatment, the
patient’s advanced disease has progressed.
The Company has been informed that a report from Dr Nagourney detailing the
patient’s treatment regime and the patient’s response to the treatment regime will be
made available once treatment and response data has been collected and analysed by
Rational Therapeutics.
-